HLB Life Science Co., Ltd. (KOSDAQ: 067630)

Market Cap	1.33T
Revenue (ttm)	97.11B
Net Income (ttm)	71.05B
Shares Out	121.81M
EPS (ttm)	671.75
PE Ratio	16.20
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	262,193
Average Volume	541,884
Open	10,650
Previous Close	10,590
Day's Range	10,590 - 10,880
52-Week Range	7,700 - 25,000
Beta	-0.09
RSI	59.70
Earnings Date	Mar 19, 2025

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co...

• Industry: Cogeneration Services and Small Power Producers
• Founded: 1998
• Employees: 145
• Stock Exchange: KOSDAQ
• Ticker Symbol: 067630

Financial Performance

In 2023, HLB Life Science's revenue was 97.99 billion, a decrease of -1.61% compared to the previous year's 99.59 billion. Losses were -5.98 billion, -88.98% less than in 2022.